Home » Boniface returns to Leverkusen as medical issues delay AC Milan transfer

Boniface returns to Leverkusen as medical issues delay AC Milan transfer

by Admin

Victor Boniface, the 24-year-old Nigerian striker, is set to return to Bayer Leverkusen today after medical concerns stalled his proposed move to AC Milan.

The forward underwent a series of tests at La Madonnina clinic and Galeazzi Hospital in Milan over the past 48 hours but was sent back to Germany without receiving clearance from the Serie A side.

The delay is believed to be linked to Boniface’s injury record, which includes two cruciate ligament tears during his time at Bodø/Glimt in 2019 and recurring muscle problems—factors that have led Milan to proceed with caution.

Providing an update on Sunday, transfer expert Fabrizio Romano confirmed that Milan’s medical team remains unconvinced, with further assessments still required. Romano stated:
“After medical tests at AC Milan, Victor Boniface returns to Germany, as there’s still no green light to his move. After 48 hours in Milano, Boniface will be back in Leverkusen today, waiting for AC Milan’s imminent decision on his medical tests/checks made over the weekend.”

The proposed deal between Milan and Leverkusen includes a €5 million loan fee with a €24 million purchase option. However, the hesitation highlights how crucial medical evaluations have become in modern football, where a player’s fitness can make or break multi-million-euro transfers.


0 comment

Related Articles

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

Log In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections

Here you'll find all collections you've created before.

Subscribe to our magazine to get news direct to your inbox.

Subscribe to our magazine to get news direct to your inbox.

You have Successfully Subscribed!